DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal cell carcinoma for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s renal cell carcinoma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with renal cell carcinoma each year?
- Of all people diagnosed with renal cell carcinoma, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal cell carcinoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Note: Coverage may vary by country
- Renal Cell Carcinoma - Epidemiology - Epidemiology Dashboard
- Renal Cell Carcinoma Epidemiology Dashboard
Author(s): Mudasir Khan, M.P.H.; Mike Hughes, M.Sc., Ph.D.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.